AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)
Close on Nov 18, 2026Market cap $145.50KP/E –Yield –
AgomAb Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €48.88M, up 24.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €48.88M | +24.3% |
| FY2024 | Dec 31, 2024 | €39.31M | +49.4% |
| FY2023 | Dec 31, 2023 | €26.31M | – |
See a number that looks wrong?